Clinicians cannot yet make a fully-informed decision to choose monotherapy or combination therapy to treat melanoma in the metastatic setting when it comes to immune therapies, but the data are sound to support combination therapy when using targeted therapies in metastatic disease, according to a Professor of Medicine at Harvard Medical School/Massachusetts General Hospital Cancer Center and Director, Termeer Center and Clinical Research in Boston, Mass.

It is uncertain if combination therapy involving targeted therapies is beneficial in the adjuvant setting, and targeted therapies are not yet on the menu in the adjuvant setting, according to Keith Flaherty, M.D.

Read the full article at